This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • S-1 Versus Capecitabine in the First Line Treatmen...
Clinical trial

S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. (SALTO)

Read time: 1 mins
Last updated:24th Jun 2013
The study is a two-arm randomised phase III trial. Patients will be randomised to receive capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the investigator. Patients will be followed 3-weekly at the outpatient clinic, toxicity will be assessed according to study protocol guidelines. Patients will be evaluated every 3 cycles for response. Upon disease progression patients will be treated according to the local investigators
Category Value
Study start date 2013-06-24

View full details